

**Table S1** Baseline characteristics of TIPS patients with cirrhosis according to muscle changes

Variables	Whole cohort (n=202)	No muscle changes (n=47)	Isolated sarcopenia (n=48)	Isolated myosteatorsis (n=19)	Combined (n=88)	P value
Age, years	55.8±11.0	52.3±9.7	49.2±10.7	60.3±9.1	60.2±9.8	<0.001
Sex						<0.001
Male	109 (54.0)	38 (34.9)	35 (32.1)	4 (3.7)	32 (29.3)	
Female	93 (46.0)	9 (9.7)	13 (14.0)	15 (16.1)	56 (60.2)	
Etiology						0.001
Viral	125 (61.9)	37 (29.6)	36 (28.8)	12 (9.6)	40 (32.0)	
Alcohol	16 (7.9)	3 (18.8)	3 (18.8)	0 (0.0)	10 (62.5)	
Autoimmune	25 (12.4)	0 (0.0)	4 (16.0)	1 (4.0)	20 (80.0)	
Others	36 (17.8)	7 (19.4)	5 (13.9)	6 (16.7)	18 (50.0)	
Smoking						0.010
Never	154 (76.2)	28 (18.2)	33 (21.4)	18 (11.7)	75 (48.7)	
Current	37 (18.3)	14 (37.8)	11 (29.7)	1 (2.7)	11 (29.7)	
Past	11 (5.4)	5 (45.5)	4 (36.3)	0 (0.0)	2 (18.2)	
Drinking						0.411
Never	166 (82.2)	36 (21.7)	37 (22.3)	18 (10.8)	75 (45.2)	
Current	24 (11.9)	7 (29.2)	6 (25.0)	1 (4.1)	10 (41.7)	
Past	12 (5.9)	4 (33.3)	5 (41.7)	0 (0.0)	3 (25.0)	
Ascites						0.219
No	76 (37.6)	24 (31.6)	19 (25.0)	6 (7.9)	27 (35.5)	
Mild	80 (39.6)	17 (21.2)	18 (22.5)	7 (8.8)	38 (47.5)	
Moderate	30 (14.9)	4 (13.3)	7 (23.3)	2 (6.7)	17 (56.7)	
Severe	16 (7.9)	2 (12.5)	4 (25.0)	4 (25.0)	6 (37.5)	
HE						0.298
No	194 (96.0)	46 (23.7)	44 (22.7)	19 (9.8)	85 (43.8)	
Yes	8 (4.0)	1 (12.5)	4 (50.0)	0 (0.0)	3 (37.5)	
PVT						0.840
No	132 (65.3)	29 (22.0)	30 (22.7)	13 (9.8)	60 (45.5)	
Yes	70 (34.7)	18 (25.7)	18 (25.7)	6 (8.5)	28 (32.9)	
CirCom score						0.484
0	165 (81.7)	36 (21.8)	40 (24.2)	17 (10.3)	72 (43.7)	
1	17 (8.4)	6 (35.3)	2 (11.8)	2 (11.8)	7 (41.1)	
3	17 (8.4)	4 (23.5)	4 (23.5)	0	9 (53.0)	
4	3 (1.5)	1 (33.3)	2 (66.7)	0	0	
INR	1.2 (1.1–1.3)	1.2 (1.2–1.3)	1.2 (1.1–1.4)	1.2 (1.1–1.3)	1.2 (1.1–1.3)	0.856
TBIL, µmol/L	25.0 (16.5–32.5)	24.0 (17.5–29.7)	19.5 (14.1–31.8)	22.7 (19.8–30.9)	25.9 (17.9–34.6)	0.554
ALB, g/L	32.7±5.5	33.4±5.6	32.7±5.3	32.3±4.1	32.3±5.8	0.715
Creatinine, µmol/L	54.7 (44.5–70.4)	57.2 (45.6–74.1)	55.1 (48.3–66.3)	53.4 (44.7–84.4)	54.1 (42.2–69.6)	0.680
Child-Pugh classification						0.336
A	74 (36.6)	22 (29.7)	20 (27.0)	6 (8.1)	26 (35.1)	
B	118 (58.4)	24 (20.3)	24 (20.3)	12 (10.2)	58 (49.2)	
C	10 (5.0)	1 (10.0)	4 (40.0)	1 (10.0)	4 (40.0)	
MELD score	10.0 (8.0–12.0)	11.0 (9.0–12.0)	10.0 (8.0–11.3)	10.0 (9.0–11.5)	10.0 (8.0–11.0)	0.488
Previous NSBB therapy						0.803
No	193 (95.5)	46 (23.8)	45 (23.3)	18 (9.3)	84 (43.5)	
Yes	9 (4.5)	1 (11.1)	3 (33.3)	1 (11.1)	4 (44.4)	
Previous endoscopic therapy						0.090
No	113 (55.9)	32 (28.3)	22 (19.5)	13 (11.5)	46 (40.7)	
Yes	89 (44.1)	15 (16.9)	26 (29.2)	6 (6.7)	42 (47.2)	

Data are expressed as mean ± SD for normally distributed continuous variables, median (IQR) for non-normally distributed continuous variables, and n (%) for categorical variables. Group comparisons were performed using *t*-tests for normally distributed continuous variables, non-parametric tests for non-normally distributed variables, and  $\chi^2$  or Fisher's exact tests for categorical variables, as appropriate. TIPS, transjugular intrahepatic portosystemic shunt; HE, hepatic encephalopathy; PVT, portal vein thrombosis; INR, international normalized ratio; TBIL, total bilirubin; ALB, albumin; MELD, Model for End-stage Liver Disease; NSBB, non-selective beta blockers; IQR, interquartile range; SD, standard deviation.